Prostate Cancer

Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses active surveillance as a treatment approach for men with prostate cancer.

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

A novel retrospective study comparing robot-assisted radical prostatectomy and radical retropubic prostatectomy, in men with high-risk prostate cancer, found equivalent oncologic outcomes.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the imminent stage migration that is likely to occur as new therapies become available expressly for metastatic prostate cancer.

The multidisciplinary clinic for patients with prostate and other GU cancers at Thomas Jefferson University Hospital has served as a model for other departments interested in providing multidisciplinary care.

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Treatment can safely be delayed in patients with low-grade prostate cancer who are carefully selected but then demonstrate disease progression after a period of active surveillance.

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Leonard G. Gomella, MD, discusses the benefits of the multidisciplinary center at Jefferson Kimmel Cancer Center.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses findings from the READY trial that added dasatinib to docetaxel as a treatment for men with metastatic castration-resistant prostate cancer.

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Administration of docetaxel every 2 weeks in patients with CRPC was associated with significantly longer time to treatment failure, improved OS, and produced fewer adverse events.

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.